Jilin Changlong Pharmaceutical (08049.HK) announced its interim results, with the profit attributable to shareholders reaching 123 million yuan, an increase of 19.25% year-on-year.

Zhitong Finance APP reported that Jilin Changlong Pharmaceutical (08049.HK) released its mid-term results for 2026, with a revenue of 436 million yuan, a year-on-year decrease of 0.87%; the profit attributable to shareholders was 123 million yuan, a year-on-year increase of 19.25%; earnings per share were 21.92 cents.